Form 4: CRBP Director Sells Shares Under 10b5-1 Plan

Corbus Pharmaceuticals director Anne Altmeyer sold 2,412 shares of common stock for a weighted average price of $7.9137 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Anne Altmeyer, a director of Corbus Pharmaceuticals Holdings, Inc. (CRBP), disposed of 2,412 shares of common stock.
• The transaction occurred on June 10, 2026, at a weighted average price of $7.9137 per share, with individual sales ranging from $7.71 to $7.97.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2026.
• Following this transaction, Anne Altmeyer beneficially owns 7,579 shares of common stock, which includes 3,800 unvested Restricted Stock Units (RSUs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine insider transaction under a pre-arranged 10b5-1 plan, which typically minimizes any negative sentiment associated with insider selling.

Industry Context

StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 trading plan are generally viewed as less indicative of management's immediate sentiment regarding the company's prospects compared to unplanned sales, as these plans are established in advance to allow insiders to sell shares systematically.

Stakeholder Impact

• Shareholders: A director's sale, even if planned, slightly increases the float and could be perceived as a minor negative, though the 10b5-1 plan mitigates this.

Key Dates

Recommendation

The sale by a director is a pre-scheduled transaction under a 10b5-1 plan and represents a relatively small portion of the director's total holdings. It does not provide a strong signal for a change in investment thesis, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Corbus Pharmaceuticals, CRBP, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Director Transaction